Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reissue Patent
2005-12-06
2005-12-06
Wang, Shengjun (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S150000, C514S477000, C514S483000, C514S562000, C514S563000, C514S596000, C514S597000, C514S598000, C514S617000, C514S618000, C514S619000, C514S616000, C514S708000, C514S762000, C514S866000
Reissue Patent
active
RE038915
ABSTRACT:
Modulation of the activity of the insulin receptor, enhancement of glucose uptake by cells, and other effects significant in the control and management of diabetes are accomplished using compounds of the formulawhereineach A is independently a proton-accepting substituent;each R is independently a noninterfering substituent;n is 0, 1, or 2; andeach linker is independently an isostere of —NHCONH— or of —N═N— or of —NHCO—.Compounds in the genus of Formula (1) can also be used for structure activity studies to identify features responsible for the relevant activities.
REFERENCES:
patent: 5217869 (1993-06-01), Kauvar
patent: 5300425 (1994-04-01), Kauvar
patent: 5587293 (1996-12-01), Kauvar et al.
patent: 5830918 (1998-11-01), Sportsman et al.
patent: 6329431 (2001-12-01), Sportsman et al.
patent: 0 172 427 (1986-02-01), None
patent: WO 95/23231 (1995-08-01), None
patent: WO 96/30762 (1996-10-01), None
patent: WO 96/40276 (1996-12-01), None
Brinkworth et al., “Non-peptidic anti-AIDS agents: inhibition of HIV-1 proteinase by disulfonates”,Biochem. Biophys. Res. Commun., 188(2), 624-630 (1992).
Desbois-Mouthon et al., “Severe resistance to insulin and insulin-like growth-factor-I in cells from a patient with leprechaunism as a result of two mutations in the tyrosine kinase domain of the insulin receptor”,Metabolism, 45, 1493-1500 (1996).
Hubbard, “Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog”,EMBO J., 16, 5572-5581 (1997).
Hubbard et al., “Crystal structure of the tyrosine kinase domain of the human insulin receptor”,Nature, 372, 746-754 (1994).
Kirchberger et al., “Studies of the interaction of NADH oxidase fromThermus thermphilusHB8 with triazine dyes”,J. Chromatogr. A, 668, 153-164 (1994).
Kletzien et al., “Enhancement of adipocyte differentiation by an insulin-sensitizing agent”,Mol. Pharmacol., 41, 393-398, (1992).
Kobayashi et al., “Pioglitazone increases insulin sensitivity by activating insulin receptor kinase”,Diabetes, 41, 476-483 (1992).
Kohanski, “Insulin receptor autophosphorylation. II. Determination of autophosphorylation sites by chemical sequence analysis and identification of the juxtamembrane sites”,Biochem., 32, 5773-5780 (1993).
Kole et al., “A synthetic peptide derived from the COOH-terminal domain of the insulin receptor specifically enhances insulin receptor signaling”,J. Biol. Chem., 271, 31619-31626 (1996).
Macaulay et al., “Mutagenic structure-function analysis of the cytoplasmic cysteines of the insulin receptor”,Biochem. J., 306, 811-820 (1995).
Maddux et al., “Evidence that insulin plus ATP may induce a conformational change in the beta subunit of the insulin receptor without inducing receptor autophosphorylation”,J. Biol. Chem., 266, 6731-6736 (1991).
Moller et al., “A naturally occurring mutation of insulin receptor alanine 1134 impairs tyrosine kinase function and is associated with dominantly inherited insulin resistance”,J. Biol. Chem., 265, 14979-14985 (1990).
Ojala et al., “The X-ray crystal structure of the sulfonated azo dye Congo Red, a non-peptidic inhibitor of HIV-1 protease which also binds to reverse transcriptase and amyloid proteins”,Antiviral. Chem. Chemother., 6, 25-33 (1995).
O'Neill et al., “Characterization of an interaction between insulin receptor substrate 1 and the insulin receptor by using the two-hybrid system”,Mol. Cell Biol., 14, 6433-6442 (1994).
Rafaeloff et al., “Transmembrane signalling by insulin via an insulin receptor mutated at tyrosines 1158, 1162, and 1163”,Biochem. Biophys. Res. Commun., 179, 912-918 (1991).
Rolband et al., “Deletion of the insulin receptor beta-subunit acidic domain results in enhanced metabolic signaling”,Endocrinology, 133, 1437-1443 (1993).
Sung et al., “Regulation of biological functions by an insulin receptor monoclonal antibody in insulin receptor beta-subunit mutants”,Biochemistry, 31, 168-174 (1992).
Ullrich et al., “Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes”,Nature, 313, 756-761 (1985).
Wei et al., “Expression, characterization and crystallization of the catalytic core of the human insulin receptor protein-tyrosine kinase domain”,J. Biol. Chem., 270, 8122-8130 (1995).
Kauvar Lawrence M.
Spevak Wayne R.
Sportsman Richard
Villar Hugo O.
Telik, Inc.
Wang Shengjun
LandOfFree
Nonpeptide insulin receptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nonpeptide insulin receptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nonpeptide insulin receptor agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3474626